Archived Insight | February 25, 2019

Bill to Repeal the Affordable Care Act’s Excise Tax on High-Cost Plans

A House bill (H.R. 748) to repeal the Affordable Care Act’s 40 percent excise tax on high-cost health plans, often referred to as the “Cadillac tax,” has been introduced by six representatives from both parties.

The 40 percent excise tax was initially scheduled to take effect in 2018. The effective date has been delayed twice. The most recent delay, to January 1, 2022, was part of last year’s Continuing Resolution to fund the federal government.

H.R. 748 would amend the Internal Revenue Code to permanently repeal the excise tax. At this time, the bill does not include any offsets for the projected federal revenue from the tax.

At the end of December 2018, the House of Representatives passed legislation to delay three Affordable Care Act taxes. The bill included a five-year delay of the medical device tax; a two-year delay of the health insurance premium tax; and one-year delay of the excise tax on high-cost plans. The Senate did not take action on this bill, and subsequent government funding bills enacted into law did not include these provisions. As Congress debates budget and appropriations bills later this year, it is possible that another delay in the excise tax could be passed.

Questions about the topic?

Get in touch.

Speak with Us

See more insights

Female Nutritionist Holding Image Of Healthy Eating Plate

Health Coaching Enhances Well-Being and Productivity

Your organization can derive significant value from integrating health coaching into its existing health-management programs.
Lawyer And Business Person Discussing In The Office

Supreme Court Addresses Prohibited Transaction Lawsuits

As a result of the Supreme Court’s decision, it will be easier for participants to sue plans for everyday plan transactions with service providers.
Pharmacist Taking Inventory With Digital Tablet

Executive Order Seeks to Lower Prescription Drug Prices

The order instructs federal departments to issue regulations or work with Congress to identify statutory changes necessary to address drug prices.

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.